Our active clinical trials offer patients and families the opportunity to participate in research that helps shape the future of vision care. These studies support the development of new treatments, technologies, and approaches for preventing, diagnosing, and managing eye disease.
The Clinical Eye Research Unit (CERU) has supported human subjects research for more than 40 years. As the department’s primary clinical research team, CERU coordinates studies ranging from small, local investigator-initiated projects to large national and global clinical trials.
Through these studies, our researchers and clinical research staff work to advance ophthalmic care, improve understanding of eye diseases, and evaluate safe and effective options for patients with vision loss. To learn more about completed studies and CERU’s ongoing contributions to vision research, visit our Clinical Trials Archive.
Age-Related Macular Degeneration
Actively Recruiting
ABID Study
This is a prospective, cross-sectional, multi-center, observational study to collect and develop a meticulously curated and diverse AMD benchmark dataset, featuring reference standard level 1 classification and comprehensive annotation of images.
GALLOP
A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy (GA) Secondary to Age Related Macular Degeneration (AMD)
Age-Related Macular Degeneration
Enrollment Closed
HONU
The purpose of this study is to assess iAMD disease progression, by the timeline and rates of conversion for high-risk iAMD at baseline to more advanced AMD stages.
LUGANO
A Phase 3, Multicenter, Prospective, Randomized, Double-Masked, Parallel-Group Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept(Eylea) in Subjects with Wet AMD
DRCR AO
Home OCT-Guided Treatment versus Treat and Extend for the Management of Neovascular AMD (Protocol AO)
Choroidal Melanoma
Actively Recruiting
DRCR AL
A Randomized Clinical Trial Evaluating Intravitreal Faricimab (6.0 mg) Injections or Fluocinolone Acetonide (0.19 mg) Intravitreal Implants vs Observation for Prevention of Visual Acuity Loss due to Radiation Retinopathy (Protocol AL)
Choroidal Melanoma
Enrollment Closed
AURA 301
A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects with Primary Intermediate Lesions or Small Choroidal Melanoma.
Cornea
Actively Recruiting
Scleral Lenses for Dry Eye
Scleral Contact Lens Reduction of Cytokines in Dry Eye Patients
NEXPEDE-1
A Randomized, Multicenter, Double-Masked, Vehicle-Controlled Phase 2/3 Study to Evaluate the Safety and Efficacy of NEXAGON (Lufepirsen Ophthalmic Gel) in Subjects with Persistent Corneal Epithelial Defects (NEXPEDE-1).
Glaucoma
Actively Recruiting
Inherited Retinal Diseases
Actively Recruiting
UNI-RARE
Universal Rare Gene Study: A Registry and Natural History Study of Retinal Dystrophies Associated with Rare Disease-Causing Genetic Variants
POLARIS
An Observational Study in Subjects to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ATP Binding Cassette Subfamily A Member 4 (ABCA4) Gene (POLARIS)
CLARICO
A Phase 1/2a Study of Subretinal Administration of OpCT-001 Photoreceptor Precursor Cells Derived From iPSCs in Patients with Primary Photoreceptor Disease
Inherited Retinal Diseases
Enrollment Closed
SOLSTICE
A Long-term Follow-up Study to Evaluate the Safety and Efficacy of Retinal Gene Therapy in Subjects with Choroideremia Treated Previously with Adeno-Associated Viral Vector Encoding Rab Escort Protein-1 (AAV2-REP1) in an Antecedent Study (SOLSTICE)
Pro-EYS
Rate of Progression in EYS Related Retinal Degeneration (Pro-EYS).
NAC Attack
NAC Attack, A Phase III, Multicenter, Randomized, Parallel, Double-Masked, Placebo-Controlled Study Evaluating the Efficacy and Safety of Oral N-Acetylcysteine in Patients with Retinitis Pigmentosa.
LUNA
B-421a-006 is a 24-month, double-masked, randomized, sham-controlled, multicenter study to evaluate the safety, tolerability, and efficacy of ultevursen in subjects with RP due to mutations in exon 13 of the USH2A gene.
Uveitis
Enrollment Closed
CLARITY
A Phase 3 Randomized, Double-Masked, Placebo-Controlled Study to Investigate the Safety and Efficacy of Oral Brepocitinib in Adults with Active, Non-Infectious Intermediate-, Posterior-, and Panuveitis